ATE142489T1 - Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen - Google Patents

Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen

Info

Publication number
ATE142489T1
ATE142489T1 AT91910048T AT91910048T ATE142489T1 AT E142489 T1 ATE142489 T1 AT E142489T1 AT 91910048 T AT91910048 T AT 91910048T AT 91910048 T AT91910048 T AT 91910048T AT E142489 T1 ATE142489 T1 AT E142489T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
pharmaceutically acceptable
glucaric acid
cellular hyperproliferation
Prior art date
Application number
AT91910048T
Other languages
English (en)
Inventor
Zbigniew Walaszek
Thomas J Slaga
Margaret Hanausek
Original Assignee
Zbigniew Walaszek
Thomas J Slaga
Margaret Hanausek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zbigniew Walaszek, Thomas J Slaga, Margaret Hanausek filed Critical Zbigniew Walaszek
Application granted granted Critical
Publication of ATE142489T1 publication Critical patent/ATE142489T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91910048T 1990-05-16 1991-05-15 Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen ATE142489T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52538490A 1990-05-16 1990-05-16

Publications (1)

Publication Number Publication Date
ATE142489T1 true ATE142489T1 (de) 1996-09-15

Family

ID=24093031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910048T ATE142489T1 (de) 1990-05-16 1991-05-15 Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen

Country Status (7)

Country Link
US (2) US5364644A (de)
EP (2) EP0730862A1 (de)
JP (1) JPH06504259A (de)
AT (1) ATE142489T1 (de)
CA (1) CA2080818A1 (de)
DE (1) DE69122099T2 (de)
WO (1) WO1991018593A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080818A1 (en) * 1990-05-16 1991-11-17 Zbigniew Walaszek Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyerproliferative disorders
FR2693876A1 (fr) * 1992-07-24 1994-01-28 Vani Complément nutritif à base de micronutriments.
BE1006217A6 (fr) * 1992-09-10 1994-06-14 Steils Anne Epouse Gerome Boisson lactee enrichie de nutriments.
CA2089607C (en) * 1992-11-05 1997-11-04 Ranjit K. Chandra Nutritional supplement for the elderly
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995035038A1 (de) * 1994-06-20 1995-12-28 Peter Singer Diätetisches lebensmittel und dessen verwendung
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US6069167A (en) * 1996-01-16 2000-05-30 University Technology Corporation Use of antioxidant agents to treat cholestatic liver disease
EP0994111B1 (de) * 1997-01-27 2003-06-04 Takara Shuzo Co. Ltd. Tetrahydrofuranderivate
WO1998041195A2 (en) 1997-03-20 1998-09-24 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
ITFI970184A1 (it) * 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
AU3221599A (en) 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
GB2337933A (en) * 1998-06-04 1999-12-08 Stephen Bloor Treating or prophylaxis of smoking related diseases
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement
US6103733A (en) * 1998-09-09 2000-08-15 Bachmann; Kenneth A. Method for increasing HDL cholesterol levels using heteroaromatic phenylmethanes
US6642259B1 (en) * 1999-05-07 2003-11-04 Trustees Of Tufts College Immune stimulating dietary supplement and method of use thereof
JP2003501393A (ja) * 1999-06-05 2003-01-14 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 心臓血管細胞増殖を阻害するための方法および組成物
SK2415U (sk) * 1999-08-17 2000-04-10 Hanzel Jaroslav Ing Prostriedok na prevenciu nedostatku jódu
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
ES2168226B1 (es) * 2000-11-27 2003-09-16 Recuperat Ion Electrolitos S L Composicion que comprende sodio, potasio, calcio y magnesio.
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US6849613B2 (en) * 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US6562378B1 (en) * 2002-08-16 2003-05-13 Tsar Health Private Ltd. Nutritional supplement for adolescents
US6565891B1 (en) * 2002-08-23 2003-05-20 Tsar Health Private Ltd. Nutritional supplement for children
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
GB2416981A (en) * 2004-08-13 2006-02-15 Nutraceuticals Ltd Premixes, flour enriched with same, mineral supplemented foodstuffs and methods of manufacture therefore.
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US20090250653A1 (en) * 2006-08-07 2009-10-08 Kiely Donald E Hydroxycarboxylic Acids and Salts
CA2660389C (en) 2006-08-07 2014-12-02 The University Of Montana Method for the preparation of organic acids via oxidization using nitric acid
DE102006040456A1 (de) * 2006-08-25 2008-02-28 Constantin Nies Verzehrbare flächige Darreichungsform von Nahrungsergänzungsmitteln und/oder Arzneiwirkstoffen zur Ergänzung von fertigen oder halbfertigen Nahrungsmitteln
US7605145B2 (en) * 2006-11-20 2009-10-20 Premier Micronutrient Corporation Micronutrient formulations for treatment of diabetes mellitus
JP5798717B2 (ja) * 2007-10-25 2015-10-21 ニュートリー株式会社 血中の糖、マロンジアルデヒド修飾ｌｄｌ、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物
WO2009065143A2 (en) * 2007-11-15 2009-05-22 The University Of Montana Hydroxypolyamide gel forming agents
EP2638184A1 (de) 2010-11-11 2013-09-18 Rivertop Renewables Korrosionsverhindernde zusammensetzung
EP2952569B1 (de) 2011-04-21 2017-01-25 Rivertop Renewables, Inc. Calciumsequestrierungszusammensetzung
WO2014085262A1 (en) 2012-11-28 2014-06-05 Rivertop Renewables Corrosion inhibiting, freezing point lowering compositions
US9187398B2 (en) 2013-03-13 2015-11-17 Rivertop Renewables, Inc. Nitric acid oxidation processes
US9346736B2 (en) 2013-03-13 2016-05-24 Rivertop Renewables, Inc. Oxidation process
US9670124B2 (en) 2013-03-13 2017-06-06 Rivertop Renewables, Inc. Nitric acid oxidation process
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
WO2021043883A1 (en) * 2019-09-05 2021-03-11 Société des Produits Nestlé S.A. Food compositions for lactating women
US20220408778A1 (en) * 2019-09-05 2022-12-29 Societe Des Produits Nestle S.A. Food compositions for lactating women
US11278520B2 (en) * 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1066885A (en) * 1964-07-29 1967-04-26 Zh Tokyo Seikagaku Kenkyukai Therapeutic agent and compositions having the inhibitory action for ª‰-glucuronidase and method of inhibiting ª‰-glucuronidase
US3697287A (en) * 1969-01-28 1972-10-10 Morton Norwich Products Inc Amino acid food composition
FR2370471A1 (fr) * 1976-11-13 1978-06-09 Kohler Valentin Agents a base d'acide glucarique possedant une activite pharmaceutique et/ou anti-microbienne
DE2651947A1 (de) * 1976-11-13 1978-05-18 Koehler Valentin Mittel mit pharmazeutischer und/oder antimikrobieller wirksamkeit
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US4845123A (en) * 1985-08-05 1989-07-04 The Ohio State University Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of β-g
US4740373A (en) * 1986-05-27 1988-04-26 Usv Pharmaceutical Corporation Stabilization of multivitamin/trace elements formulations
US5008291A (en) * 1987-08-26 1991-04-16 Ohio State University Research Foundation Method and composition for achieving chemotherapeutic activity
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
US5010107A (en) * 1987-08-26 1991-04-23 Ohio State University Research Foundation Method and composition for achieving anticarcinogenic activity
CA2080818A1 (en) * 1990-05-16 1991-11-17 Zbigniew Walaszek Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyerproliferative disorders

Also Published As

Publication number Publication date
CA2080818A1 (en) 1991-11-17
EP0730862A1 (de) 1996-09-11
US5364644A (en) 1994-11-15
EP0528950B1 (de) 1996-09-11
JPH06504259A (ja) 1994-05-19
DE69122099D1 (de) 1996-10-17
EP0528950A1 (de) 1993-03-03
US5561160A (en) 1996-10-01
WO1991018593A1 (en) 1991-12-12
EP0528950A4 (en) 1993-03-24
DE69122099T2 (de) 1997-04-17

Similar Documents

Publication Publication Date Title
DE69122099D1 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE188377T1 (de) Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
NO923199D0 (no) Terapeutiske forbindelser
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
KR890007737A (ko) 진토작용을 하는 약제